By Joshua Kirby 
 

Novartis AG has reached a deal to provide its cholesterol-lowering medicine Leqvio to patients via the U.K.'s National Health Service, the Swiss pharmaceutical company said Wednesday.

Over the course of three years, around 300,000 patients should be treated with Leqvio (inclisiran), Novartis said. The patients targeted are those at high risk of having a second cardiovascular event.

The treatment is part of a population health-management approach and aims to reduce patients' long-term elevated LDL cholesterol, a key modifiable risk factor in cardiovascular disease, the company said.

The collaboration with the NHS follows final recommendation for Leqvio from the U.K.'s medicines regulator, NICE.

 

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

 

(END) Dow Jones Newswires

September 01, 2021 01:21 ET (05:21 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Novartis.